SERO-Ab testing

  • Research type

    Research Study

  • Full title

    Covid19 Serological antibody testing in samples surplus to clinical diagnosis

  • IRAS ID

    283088

  • Contact name

    William Irving

  • Contact email

    will.irving@nottingham.ac.uk

  • Sponsor organisation

    Nottingham University Hospitals NHS Trust

  • Duration of Study in the UK

    1 years, 0 months, 7 days

  • Research summary

    Serological tests for immunity to the coronavirus SARS-CoV-2 are in their infancy, and not widely available. We will establish and validate Enzyme-linked Immunosorbent assays (ELISA) for screening for IgG, A and M responses to multiple proteins of SARS-CoV-2 to support understanding of the scope of protective immunity generated in the population. We will link the antibody response to clinical outcome of the patients to give us a better understanding of the role of antibodies in providing protection

    Excess serum samples remaining after routine diagnostic procedures have been stored by local NHS Clinical Chemistry Laboratories. These samples are from hospitalised individuals with proven SARS-CoV-2 infection.

    This multidisciplinary study will be conducted in the University of Nottingham Virology and Immunology laboratories.

    The study will last for 1 year and participants will have blood serum examined for the antibody responses to Covid19 proteins. In addition, sera will be used in neutralisation assays to determine the effectiveness of
    patient antibodies to halt viral infection (using non-infectious pseudovirus particles) and cytokine measurements.

  • REC name

    N/A

  • REC reference

    N/A